These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 24098102)
1. Target prediction for an open access set of compounds active against Mycobacterium tuberculosis. Martínez-Jiménez F; Papadatos G; Yang L; Wallace IM; Kumar V; Pieper U; Sali A; Brown JR; Overington JP; Marti-Renom MA PLoS Comput Biol; 2013; 9(10):e1003253. PubMed ID: 24098102 [TBL] [Abstract][Full Text] [Related]
2. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494 [TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
9. Virtual screening for the identification of novel inhibitors of Mycobacterium tuberculosis cell wall synthesis: inhibitors targeting RmlB and RmlC. Ren JX; Qian HL; Huang YX; Zhu NY; Si SY; Xie Y Comput Biol Med; 2015 Mar; 58():110-7. PubMed ID: 25637777 [TBL] [Abstract][Full Text] [Related]
10. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
11. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants. Jagadeb M; Rath SN; Sonawane A J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826 [TBL] [Abstract][Full Text] [Related]
12. Mycobacterium tuberculosis H37Rv LpqG Protein Peptides Can Inhibit Mycobacterial Entry through Specific Interactions. Sánchez-Barinas CD; Ocampo M; Vanegas M; Castañeda-Ramirez JJ; Patarroyo MA; Patarroyo ME Molecules; 2018 Feb; 23(3):. PubMed ID: 29495456 [No Abstract] [Full Text] [Related]
13. A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. Chiarelli LR; Mori G; Orena BS; Esposito M; Lane T; de Jesus Lopes Ribeiro AL; Degiacomi G; Zemanová J; Szádocka S; Huszár S; Palčeková Z; Manfredi M; Gosetti F; Lelièvre J; Ballell L; Kazakova E; Makarov V; Marengo E; Mikusova K; Cole ST; Riccardi G; Ekins S; Pasca MR Sci Rep; 2018 Feb; 8(1):3187. PubMed ID: 29453370 [TBL] [Abstract][Full Text] [Related]
14. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations. Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488 [TBL] [Abstract][Full Text] [Related]
15. Resisting resistant Mycobacterium tuberculosis naturally: mechanistic insights into the inhibition of the parasite's sole signal peptidase Leader peptidase B. Dhiman H; Dhanjal JK; Sharma S; Chacko S; Grover S; Grover A Biochem Biophys Res Commun; 2013 Apr; 433(4):552-7. PubMed ID: 23510997 [TBL] [Abstract][Full Text] [Related]
16. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025 [TBL] [Abstract][Full Text] [Related]
17. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
18. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis. Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598 [TBL] [Abstract][Full Text] [Related]
19. Toward the virtual screening of potential drugs in the homology modeled NAD+ dependent DNA ligase from Mycobacterium tuberculosis. Singh V; Somvanshi P Protein Pept Lett; 2010 Feb; 17(2):269-76. PubMed ID: 20214650 [TBL] [Abstract][Full Text] [Related]
20. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis. Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]